{
    "code": "60001067",
    "url": "https:\/\/info.fda.gov.tw\/MLMS\/H0001D.aspx?Type=Lic&LicId=60001067",
    "time": "2022-10-21 06:44:46",
    "許可證字號": "衛部菌疫輸字第001067號",
    "註銷狀態": "",
    "註銷日期": "",
    "註銷理由": "",
    "製造許可登錄編號": "",
    "有效日期": "116\/12\/09",
    "發證日期": "106\/12\/09",
    "許可證種類": "菌　疫",
    "舊證字號": "",
    "醫療器材級數": "",
    "第一等級醫療器材原登錄字號": "",
    "第一等級醫療器材新登錄字號": "",
    "通關簽審文件編號": "DHA06000106703",
    "中文品名": "易來力注射液150毫克\/毫升",
    "英文品名": "Ilaris 150mg\/mL solution for injection",
    "適應症": "Ilaris適用於治療成人、青少年及2歲以上兒童（體重超過7.5 kg）的Cryopyrin相關週期性症候群 (Cryopyrin-Associated Periodic Syndrome；CAPS)，包括：\r\n-\tMuckle-Wells症候群 (MWS)，\r\n-\t新生兒多重系統發炎疾病 (Neonatal-Onset Multisystem Inflammatory Disease；NOMID) \/ 慢性嬰兒神經學、皮膚、關節症候群 (Chronic Infantile Neurological, Cutaneous, Articular Syndrome；CINCA)，\r\n-\t嚴重型的家族性冷因性自體發炎症候群 (Familial Cold Autoinflammatory Syndrome；FCAS)\/家族性冷因性蕁麻疹 (Familial Cold Urticaria；FCU)，即其徵兆與症狀表現較寒冷所誘發之蕁麻性皮疹更為嚴重。",
    "劑型": "270注射劑",
    "包裝": "1毫升玻璃小瓶裝 100支以下盒裝",
    "儲存溫度": "",
    "有效期間": "",
    "指示藥品審查基準": "",
    "標籤、仿單及包裝加註": "",
    "藥品類別": "05限由醫師使用",
    "管制藥品分類級別": "",
    "藥品分類": "基因工程產品_新劑型",
    "監視期限": "",
    "主成分略述": "Canakinumab",
    "限制項目": "02輸　入 26監視期滿新藥",
    "申請商名稱": "1422701100  台灣諾華股份有限公司",
    "申請商地址": "台北市中山區民生東路三段2號8樓",
    "主製造廠": [
        {
            "製造廠名稱": "FCH0099000  NOVARTIS PHARMA STEIN AG",
            "製造廠廠址": "SCHAFFHAUSERSTRASSE CH-4332 STEIN, SWITZERLAND",
            "製造廠公司地址": "",
            "製造廠國別": "SWITZERLAND",
            "製程": ""
        }
    ],
    "次製造廠": [
        {
            "製造廠名稱": "6132061151  裕利股份有限公司",
            "製造廠廠址": "桃園市大園區和平里1鄰開和路91號",
            "製造廠公司地址": "",
            "製造廠國別": "TAIWAN",
            "製程": "二級包裝廠(委託貼標及置入仿單)"
        },
        {
            "製造廠名稱": "FFR0220000  NOVARTIS PHARMA S.A.S.",
            "製造廠廠址": "8, RUE DE L&#39;INDUSTRIE, F-68330 HUNINGUE, FRANCE",
            "製造廠公司地址": "",
            "製造廠國別": "FRANCE",
            "製程": "主成分(drug substance)製造廠"
        }
    ],
    "CCC號列": "",
    "藥理治療分類": "",
    "ingredients": [
        {
            "成分類別": "主成分",
            "成分代碼": "1013002300",
            "成分名稱": "Canakinumab",
            "含量描述": "",
            "含量": "150.0000000000",
            "單位": "MG"
        }
    ],
    "仿單外盒": [
        {
            "title": "易來力注射液-TWI-210920-回一校-109-09-24(廠商自行上傳).pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=60001067&Seq=003&Type=9"
        },
        {
            "title": "Ilaris LIVI-TWI-060919_C-109-06-10(廠商自行上傳).pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=60001067&Seq=002&Type=9"
        },
        {
            "title": "020010670001-107-01-10.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=60001067&Seq=001&Type=9"
        },
        {
            "title": "易來力注射液標籤(TWL-060919)-109-06-10(廠商自行上傳).pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=60001067&Seq=002&Type=8"
        },
        {
            "title": "020010670003-107-01-10.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=60001067&Seq=001&Type=8"
        }
    ]
}